

Ortho Regenerative Technologies technology platform front and center at 2017 ORS Annual Meeting

KIRKLAND, QC, March 24, 2017 /CNW Telbec/ - Ortho Regenerative Technologies Inc. ("**Ortho RTi**" or the "**Company**"), an emerging Orthopaedic and Sports Medicine Technology company, today announced that the results of four key scientific studies validating its product's ability to improve the repair of three distinct joint tissues - the rotator cuff tendons, the meniscus and articular cartilage - were presented at the Annual Orthopaedic Research Society ("ORS") (<http://www.ors.org>) meeting.

The ORS Annual Meeting attracts over 3,000 attendees with an interest in Orthopaedic research including clinicians, surgeons, residents, veterinarians, basic scientists, and engineers who present the latest innovative and cutting-edge musculoskeletal research. This year's ORS Annual Meeting was held this week in San Diego, CA.

The first presentation described a pilot study designed to examine the feasibility of applying the Company's proprietary Ortho-R implants in conjunction with suturing to improve rotator cuff repair. The researchers found that Ortho-R implants in conjunction with transosseous suturing improved histological structure at the supraspinatus tendons insertion site compared to suturing alone.

The second presentation was entitled "Freeze-dried chitosan-PRP injectable surgical implants for meniscus repair: results from pilot ovine studies." This presented study findings that the Company's proprietary Ortho-R implants showed superior regenerative effect over wrapping the meniscus with a collagen membrane or PRP alone, indicating that Ortho-R implants have the potential to overcome some of the current limitations of meniscus repair.

The third presentation, entitled "Freeze dried chitosan/platelet-rich-plasma implants improve marrow stimulated cartilage repair in rabbit chronic defect model", described a study that was designed to evaluate the augmentation of Bone Marrow Stimulation ("BMS") with the Company's proprietary Ortho-R implants. This presentation concluded that augmentation by Ortho-R implant improves the highly variable and less than adequate repair elicited by BMS augmented with PRP, especially in challenging and hard to treat sites.

A fourth presentation highlighted scientific results related to how various surgical procedures in the knee joint may lead to changes in meniscus inter-tie coil morphology and, thereby, affect peripheral pain.

"We believe that increasing researcher and clinician awareness of our proprietary biopolymer platform through our participation in important scientific meetings like ORS will go a long way towards advancing the technology's development and eventual product adoption," said Dr. Michael Buschmann, CSO of Ortho RTi. "This type of third-party scientific validation, where four of our studies were reviewed by external experts and selected for broad exposure at this, the most important event of its kind worldwide, is incredibly energizing."

Dr. Buschmann concluded, "It attests to the progress and excitement we are making towards validating our product for use in healing these types of injuries."

Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries. We are committed to improving patients' lives through increasing the success rates of surgeries for soft tissue injuries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at www.orthorti.com.

SOURCE Ortho Regenerative Technologies Inc.

To view the original version on PR Newswire, visit: <http://www.newswire.ca/en/releases/archive/March2017/24/c8287.html>

%SEDAR: 00037950E

For further information: please contact: Stephen Kilmer, Investor & Media Relations, 647.872.4849, kilmer@orthorti.com

CO: Ortho Regenerative Technologies Inc.

CNW 11:21e 24-MAR-17